This is a multicenter observational study with a retrospective and a prospective cohort investigating clinically and biologically the APL-like subset as a potential predictor of coagulopathy and susceptibility to early vascular events.
This is a multicenter observational study with a retrospective and a prospective cohort investigating clinically and biologically the APL-like subset as a potential predictor of coagulopathy and susceptibility to early vascular events. Participating Centers will identify NPM1-mutated patients eligible for enrollment. The immune-phenotypic data will be evaluated to define a specific signature to be applied for the identification of APL-like AML. All patients will be followed for a minimum of 12 months until the study closure.
Study Type
OBSERVATIONAL
Enrollment
220
observation of difference incidence of early vascular events in the two cohorts
Incidence of early vascular events
Evaluation of the incidence of early vascular events (haemorrhagic and/or thrombotic) in the APL-like and non-APL-like subsets.
Time frame: 30 days from diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.